Sentinel lymph node biopsy in patients with ductal carcinomain situ: systematic review and meta-analysis
Open Access
- 5 April 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 6 (2)
Abstract
Axillary lymph node status remains the most powerful prognostic indicator in invasive breast cancer. Ductal carcinoma in situ (DCIS) is a non-invasive disease and does not spread to axillary lymph nodes. The presence of an invasive component to DCIS mandates nodal evaluation through sentinel lymph node biopsy (SLNB). Quantification of the necessity of upfront SLNB for DCIS requires investigation. The aim was to establish the likelihood of having a positive SLNB (SLNB+) for DCIS and to establish parameters predictive of SLNB+. A systematic review was performed as per the PRISMA guidelines. Prospective studies only were included. Characteristics predictive of SLNB+ were expressed as dichotomous variables and pooled as odds ratios (o.r.) and associated 95 per cent confidence intervals (c.i.) using the Mantel–Haenszel method. Overall, 16 studies including 4388 patients were included (mean patient age 54.8 (range 24 to 92) years). Of these, 72.5 per cent of patients underwent SLNB (3156 of 4356 patients) and 4.9 per cent had SLNB+ (153 of 3153 patients). The likelihood of having SLNB+ for DCIS was less than 1 per cent (o.r. P < 0.001, I2 = 93 per cent). Palpable DCIS (o.r. 2.01, 95 per cent c.i. 0.64 to 6.24; P = 0.230, I2 = 0 per cent), tumour necrosis (o.r. 3.84, 95 per cent c.i. 0.85 to 17.44; P = 0.080, I2 = 83 per cent), and grade 3 DCIS (o.r. 1.34, 95 per cent c.i. 0.80 to 2.23; P = 0.270, I2 = 0 per cent) all trended towards significance in predicting SLNB+. While aggressive clinicopathological parameters may guide SLNB for patients with DCIS, the absolute and relative risk of SLNB+ for DCIS is less than 5 per cent and 1 per cent, respectively. Well-designed randomized controlled trials are required to establish fully the necessity of SLNB for patients diagnosed with DCIS. CRD42021284194 (https://www.crd.york.ac.uk/prospero/)Keywords
Funding Information
- National Breast Cancer Research Institute
This publication has 59 references indexed in Scilit:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the BreastJNCI: Journal of the National Cancer Institute, 2013
- Risk predictors of underestimation and the need for sentinel node biopsy in patients diagnosed with ductal carcinoma in situ by preoperative needle biopsyJournal of Surgical Oncology, 2012
- Ductal Carcinoma In Situ of the BreastInternational Journal of Surgical Oncology, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node MetastasisJAMA, 2011
- Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 casesBreast Cancer Research and Treatment, 2006
- Core biopsy diagnosis of ductal carcinoma in situ: An indication for sentinel lymph node biopsyCurrent Surgery, 2005
- A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast CancerNew England Journal of Medicine, 2003
- Sentinel Lymph Node Biopsy: Is It Indicated in Patients With High-Risk Ductal Carcinoma-In-Situ and Ductal Carcinoma-In-Situ With Microinvasion?Annals of Surgical Oncology, 2000